---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-121017"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2021-09-30T23:59:59+00:00"
generated_at: "2026-06-29T00:16:34.767250+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eloxx enters $50M at-the-market equity distribution agreement with SVB Leerink

## Summary
- Up to $50M in common stock may be sold through SVB Leerink as sales agent under ATM program.
- SVB Leerink receives 3% commission on gross sales proceeds; company provides customary indemnification.
- Shares sold pursuant to existing S-3 shelf registration and prospectus supplement dated Sept 30, 2021.
- Company is not obligated to sell any shares; agreement can be terminated by either party at any time.

## SEC filing metadata
- accession: 0001104659-21-121017
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2021-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465921121017/0001104659-21-121017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465921121017/tm2128746d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-121017
- JSON: https://secwatch.observer/filing/0001104659-21-121017.json
- Plain text: https://secwatch.observer/filing/0001104659-21-121017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.